Statement of Deviation or Variation in ultilization of Funds under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bacil Pharma Limited has submitted a confirmation to BSE that the company did not raise any funds during the quarter ended 31st March 2026 through public issues, rights issues, preferential issues, QIP, or any other mode of fundraising. Since no funds were raised, the requirement to file a Statement of Deviation or Variation in fund utilization under SEBI Regulation 32 is not applicable to the company for this quarter. The filing is signed by Ms. Chaitali Kalpataru Shah, Director & CFO, and dated 22 May 2026.
No direct impact on shareholders or stock price as this is a routine compliance confirmation that no fund-raising occurred during the quarter.